DDInter458 DDInter821
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder in which the overproduction of toxic heme intermediates leads to neuro-, nephro-, and gastrotoxicity. Givosiran represents an important step forward in the treatment of acute hepatic porphyria as it is the first approved pharmacotherapy for the prevention of acute attacks - previous strategies involved non-therapeutic measures (e.g. trigger avoidance), intravenous [hemin] for the treatment of attacks, and liver transplantation in refractory cases. Givosiran is the second-ever FDA-approved member of the siRNA drug class (the first being [patisiran]), a new class of drugs promising an important and exciting step forward in the treatment of genetic disorders.
Cyclosporine {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Dexfenfluramine
Dexfenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Givosiran
Cyclosporine {u} (Compound) downregulates {v} (Gene) DNMT1
DNMT1 {u} (Gene) is bound by {v} (Compound) Flucytosine
Flucytosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Givosiran
Cyclosporine {u} (Compound) upregulates {v} (Gene) COPB2
COPB2 {u} (Gene) is upregulated by {v} (Compound) Flucytosine
Flucytosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Givosiran
Cyclosporine {u} (Compound) upregulates {v} (Gene) COPB2
COPB2 {u} (Gene) is downregulated by {v} (Compound) Pentamidine
Pentamidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Givosiran
Cyclosporine {u} (Compound) upregulates {v} (Gene) EDEM1
EDEM1 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Givosiran
Cyclosporine {u} (Compound) binds {v} (Gene) ABCC2
ABCC2 {u} (Gene) is bound by {v} (Compound) Tamoxifen
Tamoxifen {u} may lead to a major life threatening interaction when taken with {v} Givosiran
Cyclosporine {u} (Compound) downregulates {v} (Gene) GRWD1
GRWD1 {u} (Gene) is downregulated by {v} (Compound) Flucytosine
Flucytosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Givosiran
Cyclosporine {u} (Compound) downregulates {v} (Gene) GRWD1
GRWD1 {u} (Gene) is downregulated by {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Givosiran
Cyclosporine {u} (Compound) downregulates {v} (Gene) LIG1
LIG1 {u} (Gene) is upregulated by {v} (Compound) Methotrexate
Methotrexate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Givosiran
Cyclosporine {u} (Compound) causes {v} (Side Effect) Anorexia
Anorexia {u} (Side Effect) is caused by {v} (Compound) Flucytosine
Flucytosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Givosiran
Cyclosporine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Dexfenfluramine (Compound) and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Cyclosporine (Compound) downregulates DNMT1 (Gene) and DNMT1 (Gene) is bound by Flucytosine (Compound) and Flucytosine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Cyclosporine (Compound) upregulates COPB2 (Gene) and COPB2 (Gene) is upregulated by Flucytosine (Compound) and Flucytosine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Cyclosporine (Compound) upregulates COPB2 (Gene) and COPB2 (Gene) is downregulated by Pentamidine (Compound) and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Cyclosporine (Compound) upregulates EDEM1 (Gene) and EDEM1 (Gene) is upregulated by Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Givosiran
Cyclosporine (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Tamoxifen (Compound) and Tamoxifen may lead to a major life threatening interaction when taken with Givosiran
Cyclosporine (Compound) downregulates GRWD1 (Gene) and GRWD1 (Gene) is downregulated by Flucytosine (Compound) and Flucytosine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Cyclosporine (Compound) downregulates GRWD1 (Gene) and GRWD1 (Gene) is downregulated by Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Givosiran
Cyclosporine (Compound) downregulates LIG1 (Gene) and LIG1 (Gene) is upregulated by Methotrexate (Compound) and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Cyclosporine (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Flucytosine (Compound) and Flucytosine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran